EMA Accepts Pegfilgastim Biosimilar for Review
The agency will review Mylan and Biocon’s biosimilar to pegfilgrastim.
On July 21, 2016 Mylan and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Application (MAA) for its proposed biosimilar to pegfilgrastim. The drug was co-developed by Biocon and Mylan and is used to treat cancer patients. The drug minimizes the side effects of chemotherapy treatment, reducing the duration of neutropenia. According to Mylan, in addition to analytical, functional, and preclinical data, the application includes clinical data from pharmacokinetic/pharmacodynamic (PK/PD) studies completed earlier in 2016.
This comes after FDA sent a complete response letter to Sandoz for Neulasta, its biosimilar candidate to pegfilgrastim. Novartis released a statement in its Q2 report saying the company is working with FDA to address remaining questions.
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.
